Onaseron ODT 4 mg (Dispersible Tablet)
Unit Price: ৳ 5.00 (3 x 10: ৳ 150.00)
Strip Price: ৳ 50.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ondansetron |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy
- Prevention and treatment of post-operative nausea and vomiting
- Prevention of radiotherapy-induced nausea and vomiting
Description
- Orally dissolving film
- Applied on top of the tongue
- Dissolves within 20 seconds
- Swallowed with saliva
- Does not require water for dissolution or swallowing
- Active ingredient: Onaseron ODT base
- Selective blocking agent of the serotonin 5-HT3 receptor type
- Empirical formula: C18H19N3O
- Molecular weight: 293.3
Pharmacology
- Potent, highly selective 5HT3 receptor-antagonist
- Precise mode of action not fully known
- Blocks initiation of vomiting reflex
- Antagonizes 5HT3 receptors in peripheral and central nervous system
- Mechanisms of action in post-operative nausea and vomiting not fully known
Dosage
- Different dosages for adults and pediatric patients
- Oral tablets/orodispersible tablets available in 4mg and 8mg
- Injection available
- Dosage based on chemotherapy/radiotherapy type and patient weight
- Instructions for different age groups and types of chemotherapy/radiotherapy
- Oral solution dosages for different types of chemotherapy/radiotherapy
- Instructions for administration with and without radiotherapy
- Oral soluble film dosages for different chemotherapy/radiotherapy types
Administration
- Instructions for administration of oral soluble film
- Step-by-step guide for administration
Interaction
- Metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes
- Inducers or inhibitors of these enzymes may affect clearance and half-life
Contraindications
- Hypersensitivity to the drug or any of its components
- Concomitant use of apomorphine
Side Effects
- Frequently reported adverse events: headache, constipation, diarrhea
- Mild to moderate adverse events
- Rash reported in chemotherapy-induced nausea and vomiting
- Rare cases of anaphylaxis, bronchospasm, tachycardia, chest pain, hypokalemia, shortness of breath
- Reports of flushing, warmth sensation, hiccups, liver enzyme abnormalities
- No evidence of extrapyramidal reactions
- Rates of adverse events compared to placebo
Pregnancy & Lactation
- Carcinogenic effects not seen in animal studies
- Not mutagenic in standard tests
- No evidence of impaired fertility or harm to fetus in animal studies
- Caution advised during breastfeeding due to excretion in breast milk
Precautions & Warnings
- Hypersensitivity reactions reported
- Not a drug that stimulates gastric or intestinal peristalsis
- Caution following abdominal surgery or in chemotherapy-induced nausea and vomiting
Use in Special Populations
- Dosage adjustment for impaired hepatic function
- Limited information on dosage for pediatric patients 4 years of age or younger
Therapeutic Class
- Anti-emetic drugs
Storage Conditions
- Store at temperature not exceeding 30°C
- Dry place
- Protect from light and moisture